
Pfizer recall two batches of migraine drug Relpax
pharmafile | August 16, 2019 | News story | Medical Communications | FDA, Pfizer, Relpax, migraine, pharma, recall
Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination.
In a statement on the FDA website, Pfizer said: “Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections.”
However the firm said the risk of infection was low for the general population. The risk may be higher for those with compromised immune systems, cystic fibrosis and chronic granulomatous disease.
The two lots of 40mg tablets are labelled AR5407 and CD4565. Pfizer has not yet received any complaints or reports of adverse events relating to the batches.
Louis Goss
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …





